Immunological adjuvants. VI. An acetylated mycobacterial adjuvant lacking competing antigenicity. 1971

A Tanaka, and T Ishibashi, and K Sugiyama, and M Takamoto

UI MeSH Term Description Entries
D008297 Male Males
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D010047 Ovalbumin An albumin obtained from the white of eggs. It is a member of the serpin superfamily. Serpin B14
D003315 Cornea The transparent anterior portion of the fibrous coat of the eye consisting of five layers: stratified squamous CORNEAL EPITHELIUM; BOWMAN MEMBRANE; CORNEAL STROMA; DESCEMET MEMBRANE; and mesenchymal CORNEAL ENDOTHELIUM. It serves as the first refracting medium of the eye. It is structurally continuous with the SCLERA, avascular, receiving its nourishment by permeation through spaces between the lamellae, and is innervated by the ophthalmic division of the TRIGEMINAL NERVE via the ciliary nerves and those of the surrounding conjunctiva which together form plexuses. (Cline et al., Dictionary of Visual Science, 4th ed) Corneas
D005260 Female Females
D005620 Freund's Adjuvant An antigen solution emulsified in mineral oil. The complete form is made up of killed, dried mycobacteria, usually M. tuberculosis, suspended in the oil phase. It is effective in stimulating cell-mediated immunity (IMMUNITY, CELLULAR) and potentiates the production of certain IMMUNOGLOBULINS in some animals. The incomplete form does not contain mycobacteria. Freund Adjuvant,Adjuvant, Freund,Adjuvant, Freund's,Freunds Adjuvant
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000937 Antigen-Antibody Reactions The processes triggered by interactions of ANTIBODIES with their ANTIGENS. Antigen Antibody Reactions,Antigen-Antibody Reaction,Reaction, Antigen-Antibody,Reactions, Antigen-Antibody

Related Publications

A Tanaka, and T Ishibashi, and K Sugiyama, and M Takamoto
January 1968, International archives of allergy and applied immunology,
A Tanaka, and T Ishibashi, and K Sugiyama, and M Takamoto
January 1969, International archives of allergy and applied immunology,
A Tanaka, and T Ishibashi, and K Sugiyama, and M Takamoto
January 1992, Advances in experimental medicine and biology,
A Tanaka, and T Ishibashi, and K Sugiyama, and M Takamoto
August 1961, Deutsche medizinische Wochenschrift (1946),
A Tanaka, and T Ishibashi, and K Sugiyama, and M Takamoto
May 2000, Biochemical and biophysical research communications,
A Tanaka, and T Ishibashi, and K Sugiyama, and M Takamoto
April 1974, Canadian journal of microbiology,
A Tanaka, and T Ishibashi, and K Sugiyama, and M Takamoto
January 1995, Advances in experimental medicine and biology,
A Tanaka, and T Ishibashi, and K Sugiyama, and M Takamoto
January 1992, Vaccine,
A Tanaka, and T Ishibashi, and K Sugiyama, and M Takamoto
January 1982, Progress in clinical and biological research,
A Tanaka, and T Ishibashi, and K Sugiyama, and M Takamoto
January 1995, Pharmaceutical biotechnology,
Copied contents to your clipboard!